milvexian

selective factor Xia serine protease inhib.

oral, phase II, cardiovascular

from opt. of previous macrocyclic FXIa inh.

Journal of Medicinal Chemistry

Bristol Myers Squibb

The BMS factor XIa inhibitor, milvexian (BMS-986177), is an oral antithrombotic with a Ki of 0.11 nM. A member of this macrocyclic series was previously highlighted as one of 2020’s Molecules of…

become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

Stay up-to-date and save more time with exclusive members-only content
On-board new team members with educational content and case studies

Generate ideas and discussion with easy-to-read slide decks
Generate ideas and discussion with easy-to-read slide decks